AZN vs GRFS

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

GRFS presents a classic 'value trap' profile: strong deterministic health (Piotroski F-Score 7/9) and deep valuation discounts (Price < Graham Number < Intrinsic Value), yet it suffers from severe market rejection. While the stock trades at a significant discount to its Graham Number of $11.36 and Intrinsic Value of $18.88, this is offset by a 0/100 technical trend and a dismal earnings track record with 0 beats in the last 4 quarters. The disconnect between strong operational health scores and poor price performance suggests systemic risks or lack of catalyst for a reversal.